Liquidia
At Liquidia, we are dedicated to developing best-in-class therapies for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to help patients breathe easier and live longer.
Private Company
Total funding raised: $195M
About
At Liquidia, we are dedicated to developing best-in-class therapies for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to help patients breathe easier and live longer.
Drug DeliveryNanotechnology
Funding History
5Total raised:$195M
PIPE$100M
IPO$40M
Series C$25M
Series B$20M